UTHR vs ZBH
United Therapeutics vs Zimmer Biomet — AI-powered side-by-side comparison
UTHR
United Therapeutics
70
Buy
VS
| Metric | UTHR | ZBH |
|---|
| AI Score |
70
|
70
|
| Price |
$538.75
|
$96.61
|
| P/E Ratio |
17.82×
|
23.38×
|
| ROE |
18.8%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
86.1%
|
69.9%
|
| Debt / Equity |
0.00×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
66.9
|
58.9
|
| Beta |
0.58
|
0.468
|
| Expected Upside |
+4.6%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for UTHR versus ZBH.
The committee scores are tied.
UTHR and ZBH both score 70/100.
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 15.0% downside vs 4.6% upside.
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.